Related Experiment Videos
[Present treatment strategies for rectal carcinoma]
T Liersch1, C Langer, B M Ghadimi
1Klinik für Allgemeinchirurgie, Universitätsklinikum Göttingen.
Summary
Recent advancements in rectal cancer treatment offer stage-dependent strategies. Early-stage rectal carcinomas are treated with local excision or resection, while advanced stages benefit from neoadjuvant chemoradiotherapy and surgery, improving survival rates.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- Significant progress in rectal cancer management over the past decade.
- Evolving interdisciplinary staging guides treatment decisions.
- Established multimodal treatment protocols for rectal carcinomas.
Purpose:
- To outline stage-dependent treatment strategies for rectal cancer.
- To highlight the role of neoadjuvant chemoradiotherapy and surgical techniques.
- To present outcomes of multimodal therapy for advanced rectal cancer.
Summary:
- Low-risk pT1 rectal carcinomas are managed with local excision.
- High-risk pT1 and pT2 carcinomas necessitate transabdominal resection.
- Locally advanced rectal cancers (cUICC-II/-III) require neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy followed by surgery and adjuvant chemotherapy.
- Key surgical principles include the "no-touch" technique, radicular vessel dissection, and total mesorectal excision.
- This multimodal approach achieved a 5-year local recurrence rate of 6%, with 68% disease-free survival and 76% overall survival in advanced cases.
Impact:
- Improved outcomes for rectal cancer patients through tailored, multimodal therapy.
- Reduced local recurrence rates in advanced rectal cancer.
- Enhanced disease-free and overall survival following standardized treatment protocols.